Research Study

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)
Principal Investigator 
Eric M. Yoshida

Overview

Body Locations and Systems 
Hepatitis C
ClinicalTrials.gov# 
NCT02581189
Status 
Recruiting
Study Start/End 
Dec 15, 2015 to Nov 1, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jo-Ann Ford, Study Coordinator
Phone 
604-875-5705
Email Address 
joann.ford@vch.ca
Purpose of Study 

This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free ABBVIE REGIMEN ± RBV in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Canada.
 

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.